EMA Authorised: Stelara (ustekinumab) — Janssen-Cilag International NV

View source ↗

Summary

The EMA has authorised Stelara (ustekinumab) in the EU for psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease;Colitis, Ulcerative. MAH: Janssen-Cilag International NV. Decision date: 07/04/2026